Agonist News and Research

RSS

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes.

13 Nov 2023

Cannabis and derivatives show promise in reducing weight and waist circumference, with nuanced effects on body fat

The study in the International Journal of Obesity reports that cannabis and its derivatives may influence weight and waist circumference, with different effects on body fat, suggesting potential as a therapeutic aid in obesity management.

8 Nov 2023

Scientists identify progenitor cells that could revolutionize osteoarthritis treatment

Researchers report that osteoarthritis is caused by the loss of Gremlin 1 (Grem1)-lineage chondrogenic progenitor cells.

3 Nov 2023

Does the timing of prenatal exposure to corticosteroids and β2-agonists impact a child's neurodevelopment by age 3?

Researchers investigated the association between the timing of in-utero exposure to β2-agonists and corticosteroids and offspring neurodevelopmental milestones during the initial three years of life.

26 Oct 2023

Researchers discover new way to trigger programmed cell death in cancer cells

A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.

24 Oct 2023

Ketamine's long-lasting antidepressant effects unveiled in new study

Persistent blocking of NMDAR and burst-type firing by lateral habenula (LHb) neurons may offer a basis for the long-lasting antidepressant effects of ketamine.

22 Oct 2023

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

The study reveals a significant increase in the usage of GLP-1 receptor agonists, particularly Ozempic and Trulicity, for weight management and Type 2 diabetes in the U.S. from 2014 to 2022. Amidst rapid growth and shortages, the paper calls for evidence-based decision-making to ensure stable medication supply and effective treatment.

17 Oct 2023

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

In a groundbreaking 84-week-long study, researchers found that tirzepatide, a medication initially designed for treating type 2 diabetes, significantly bolstered weight loss in overweight and obese patients already on intensive lifestyle programs. While the drug showed promise in further reducing body weight and improving cardiometabolic factors, mild to moderate gastrointestinal side effects were the most common drawback.

16 Oct 2023

What are the effects of smoking cessation on vascular endothelial function?

The effects of smoking cessation on vascular endothelial function.

16 Oct 2023

GLP-1 weight loss drugs linked to heightened GI risks, says new study

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

5 Oct 2023

The metabolic effects of endocrine therapy on diabetes mellitus in breast cancer survivors

Researchers discuss the history of endocrine therapies, highlights their adverse metabolic effects, and emphasizes the need for better biomarkers of diabetes.

5 Oct 2023

Radiation therapy combined with two types of immunotherapy could be effective against cold tumors

Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two types of immunotherapy-;one that boosts T cells, and another that boosts dendritic cells-;can control tumors in preclinical models of triple negative breast cancer, a cancer type that's typically resistant to immunotherapy alone.

25 Sep 2023

Research could lead to the development of new weight-loss drug that mimics exercise

A brand-new kind of drug, tested in mice, shows promising new results that could lead to the development of a new weight-loss drug that mimics exercise.

25 Sep 2023

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Meta-analysis finds tirzepatide to be the most effective GLP-1 receptor agonist for glucose and weight control in type 2 diabetes patients. The study suggests tirzepatide could be preferable in initial stages of the disease, while other GLP-1 receptor agonists combined with insulin are equally effective for long-term diabetics.

25 Sep 2023

COVID-19 pandemic fails to deter osteoporosis treatment initiation: New study reveals steady rates

Whether patients with newly diagnosed osteoporosis received delayed pharmacologic treatment due to the COVID-19 pandemic.

18 Sep 2023

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Groundbreaking research published today in Nature Genetics describes the largest-ever study into the genetics of random "round-the-clock" blood glucose levels.

8 Sep 2023

Rethinking menopause: Experts call for individualized treatment and more research

A comprehensive review in the journal Cell provides an in-depth look at the biology, clinical outcomes, and treatment options for menopause, including the effects of hormonal changes on metabolic and cognitive functions. The article also discusses various therapeutic interventions, from hormone therapy to alternative medicines, and their efficacy in managing menopausal symptoms.

7 Sep 2023

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

The study reveals that oral semaglutide, a medication primarily used for type 2 diabetes, effectively reduces body weight and blood glucose levels in diet-induced obese mice. The findings suggest that this drug could be a promising treatment for obesity and offer a suitable animal model for future research.

3 Sep 2023

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Researchers evaluated the efficacy of semaglutide in patients with the obesity phenotype of heart failure and preserved ejection fraction.

31 Aug 2023

Semaglutide could be a game-changer for patients with HFpEF and obesity

Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

25 Aug 2023

Agonist News and Research

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

Cannabis and derivatives show promise in reducing weight and waist circumference, with nuanced effects on body fat

Scientists identify progenitor cells that could revolutionize osteoarthritis treatment

Does the timing of prenatal exposure to corticosteroids and β2-agonists impact a child's neurodevelopment by age 3?

Researchers discover new way to trigger programmed cell death in cancer cells

Ketamine's long-lasting antidepressant effects unveiled in new study

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

What are the effects of smoking cessation on vascular endothelial function?

GLP-1 weight loss drugs linked to heightened GI risks, says new study

The metabolic effects of endocrine therapy on diabetes mellitus in breast cancer survivors

Radiation therapy combined with two types of immunotherapy could be effective against cold tumors

Research could lead to the development of new weight-loss drug that mimics exercise

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

COVID-19 pandemic fails to deter osteoporosis treatment initiation: New study reveals steady rates

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Rethinking menopause: Experts call for individualized treatment and more research

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Semaglutide could be a game-changer for patients with HFpEF and obesity

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News